According to researchers at Wuhan University, more than 3 billion people worldwide currently suffer from obesity, a figure forecasted to exceed 4 billion by 2035. To combat weight rebound and inflammation-suppressed fat browning linked to single-agent therapies, scientists developed an adipose-targeted composite microneedle patch named LRSG-SG@MN, which co-delivers semaglutide and rosiglitazone to modulate immune response and stimulate thermogenic fat energy consumption.
The worldwide obesity crisis presents an escalating challenge for global public health systems. According to data published in Nano Research by Weiqin Yao, Jiawen Wang, Xuan Zeng, and Weihai Chen, over 3 billion individuals live with obesity, and projections indicate that total will surpass 4 billion by 2035. This scale affects more than half the global population, driving non-communicable health threats including type 2 diabetes, cardiovascular illnesses, metabolic fatty liver disease, and various cancers through persistent visceral adipose inflammation.
Overcoming the Limitations of Single-Agent Obesity Treatments
Mainstream interventions rely heavily on semaglutide, a GLP-1 agonist approved for weight loss. According to the research team at Wuhan University, semaglutide works by activating central hypothalamic GLP-1 receptors to regulate systemic energy balance and suppress appetite. However, this brain-centered mechanism lacks durability. Once treatment stops, patients experience rapid weight regain, severely limiting long-term metabolic benefits.
Previous efforts to pair semaglutide with adipose-targeted browning compounds to boost fat energy consumption hit a biological roadblock. Chronic inflammatory adipose microenvironments block thermogenic gene expression, rendering single-agent enhancements largely ineffective. Recognizing this barrier, the Wuhan University team discovered an overlooked peripheral immunomodulatory property of semaglutide to shift treatment strategies.
Dual-Mechanism Synergistic Therapy via Microneedle Delivery
Beyond its central appetite-regulating functions, semaglutide binds directly to GLP-1 receptors on adipose macrophages. According to the published study, this binding drives macrophages to shift from pro-inflammatory M1 subtypes to anti-inflammatory M2 subtypes, successfully easing local adipose inflammation. This discovery inspired a synergistic dual-drug therapy pairing semaglutide with rosiglitazone, a PPAR-γ agonist known to stimulate white fat browning.
Pro Tip: Localized Transdermal Delivery
To achieve localized, sustained co-delivery, scientists tuned a composite microneedle patch from hyaluronic acid, gelatin, and gelatinized starch. Nano-lipid nanoparticles carrying both active compounds are embedded directly within the patch to ensure slow degradation and long-term subcutaneous release.
Once applied, the system resolves key physiological obstacles. Semaglutide reshapes the immune landscape of fat tissue by reducing inflammation and adipocyte oxidative stress, thereby creating supportive conditions for fat browning. Simultaneously, lipid nanocarriers selectively deliver rosiglitazone into adipocytes to activate PPAR-γ signaling, accelerating the thermogenic browning of white fat.
Preclinical Performance and Biosafety
Testing on high-fat diet-induced obese mouse models yielded measurable metabolic improvements. According to the research findings funded by the National Natural Science Foundation of China (Nos. 52273148, 52333004, and 52473145), the microneedle system achieved potent weight reduction and alleviated glucolipid metabolic disorders. Crucially, subjects avoided significant weight rebound after treatment withdrawal while maintaining satisfactory biosafety performance.
Did You Know?
Frequently Asked Questions
What causes rapid weight regain after stopping traditional semaglutide treatments?
According to the Wuhan University researchers, semaglutide’s standard mechanism relies on central hypothalamic GLP-1 receptors to suppress appetite. Without addressing the underlying peripheral inflammation in adipose tissue, halting treatment leads to rapid weight rebound.
How does the LRSG-SG@MN microneedle patch work?
The patch uses a slow-degrading matrix of hyaluronic acid, gelatin, and gelatinized starch embedded with nano-lipid nanoparticles. This delivers semaglutide and rosiglitazone directly into subcutaneous fat tissue to reduce inflammation and stimulate fat browning simultaneously.
What role does rosiglitazone play in the dual-drug therapy?
Rosiglitazone acts as a PPAR-γ agonist. When selectively delivered into adipocytes by lipid nanocarriers, it activates signaling pathways that accelerate the thermogenic browning of white fat.
Which funding bodies supported this research?
According to the study details, the work was supported by the National Natural Science Foundation of China under grant numbers 52273148, 52333004, and 52473145.
Stay Informed on Metabolic Health Breakthroughs
Explore our latest coverage on biomedical innovations, or subscribe to our research updates for weekly scientific insights.
Related reading